• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Biohaven Pharmaceuticals

Your company is a joke. Offices laughing . Good luck catching up if you finally do launch or don’t get sold to another company.

My offices (who I have great relationships with) aren't laughing? Are your offices laughing? As a matter of fact they're quite excited for our product to launch..S U B L I N G U A L hehe
 












What kind of a question is this?? Will insurance pay for it? Are you a seasoned rep? Of course insurance won’t pay for it! Especially from the start. Get ready to do PAs, pull through and all the other nonsense we have to deal with. And, of course, go against monsters like Allergan to fight their new drugs. Good luck!

You will be fighting for table crumbs from a marketplace perspective, and Allergan will eat your breakfast, lunch and dinner. The level of staffing is consistent with launching a drug in the 90s; times have changed.
 




You will be fighting for table crumbs from a marketplace perspective, and Allergan will eat your breakfast, lunch and dinner. The level of staffing is consistent with launching a drug in the 90s; times have changed.

I am sure they will use the same sales force to promote the other drugs in the pipeline.
 
























Regardless of the fact that Allergan launched 1st, Biohaven has the better product. Allergan better get what they can while they can whenever wherever because once we lunch they will be the one's begging for favors.
 




Regardless of the fact that Allergan launched 1st, Biohaven has the better product. Allergan better get what they can while they can whenever wherever because once we lunch they will be the one's begging for favors.
Don’t kid yourself, you are all going to begging for favors.


The Institute for Clinical and Economic Review's new draft report on Eli Lilly’s Reyvow, Allergan’s ubrogepant and Biohaven’s rimegepant concludes with “moderate certainty” the drugs provide a “small or substantial” health benefit for patients who can’t take or haven't responded to triptans, a class of older migraine treatments.

But for those who can, ICER rated ubrogepant and rimegepant as “comparable or inferior” to the existing meds. And Lilly’s Reyvow is likely to perform worse than the existing options, the group said.
 




Don’t kid yourself, you are all going to begging for favors.


The Institute for Clinical and Economic Review's new draft report on Eli Lilly’s Reyvow, Allergan’s ubrogepant and Biohaven’s rimegepant concludes with “moderate certainty” the drugs provide a “small or substantial” health benefit for patients who can’t take or haven't responded to triptans, a class of older migraine treatments.

But for those who can, ICER rated ubrogepant and rimegepant as “comparable or inferior” to the existing meds. And Lilly’s Reyvow is likely to perform worse than the existing options, the group said.

https://pioneerinstitute.org/featur...o-determine-cost-effectiveness-of-treatments/

this group is questionable but use it as your excuse .. for whatever .. sad pathetic new company with no approval ..
 




Allergan rep, you are an ass. Sure Biohaven is a cluster and will self implode, that does not make you and your sleazy company any better. You will get it soon enough.



Allergan Rep, already promoting in field. Ha , I will leave you a few bread crumbs you can have LOL LOL

enjoy your 6 month severance!!!!!JAAAAAAA HAAAAAA
 








Allergan Rep, already promoting in field. Ha , I will leave you a few bread crumbs you can have LOL LOL

enjoy your 6 month severance!!!!!JAAAAAAA HAAAAAA


Allergan primary care lifers and what they call specialty reps (also primary care reps) will be in the unemployment line standing right next to Biohaven reps . Abbvie will slit throats when they buy Allergan.
 








Allergan primary care lifers and what they call specialty reps (also primary care reps) will be in the unemployment line standing right next to Biohaven reps . Abbvie will slit throats when they buy Allergan.


This board seem to forget that most migraine patients are already on Ajovy, Aimovig or Evenity. It shows the inexperience of this company to think Allergan is the competition.
 




This board seem to forget that most migraine patients are already on Ajovy, Aimovig or Evenity. It shows the inexperience of this company to think Allergan is the competition.

All Migraine products are our competition of course. There has been more talk around Allergan because they have the newer product with closest similarities to ours. Duhhh
 




This board seem to forget that most migraine patients are already on Ajovy, Aimovig or Evenity. It shows the inexperience of this company to think Allergan is the competition.

you’ve obviously not sold migraine meds...or if you have, I hope you’re with Allergan most patients on a preventative (ajovy, aim, emg) will still have breakthrough migraines & require acute/abortive meds. The new preventatives are great, but they’re not a cure for migraine. Some patients aren’t bad enough to require a preventative & those three products aren’t indicated for use unless the patient has multiple migraines a month. If you talk to a migraine sufferer, you’ll find they’re on a cocktail of multiple meds in most cases ...triptans & allergans product is Biohaven’s competition...